Topletz-Erickson, Ariel R.
Lee, Anthony J.
Mayor, JoAl G.
Sun, Hao
Abdulrasool, Layth I.
Rustia, Evelyn L.
Walker, Luke N.
Endres, Christopher J.
Funding for this research was provided by:
Seagen Inc
Article History
Accepted: 12 October 2022
First Online: 5 December 2022
Declarations
:
: Funding for this publication was provided by Seagen Inc. (Bothell, Washington, USA).
: This study was funded by Seagen Inc. The authors wrote the article with the assistance of a medical writer funded by the sponsor. All the authors had full access to the relevant data, vouch for the completeness and accuracy of the data and for adherence of the trial to the protocol, assume final responsibility for the content of the article, and for the decision to submit the article for publication. A.R. Topletz-Erickson, A.J. Lee, J.G. Mayor, H. Sun, L.I. Abdulrasool, and C.J. Endres are employees of Seagen Inc., and hold stocks and shares in Seagen Inc. E.L. Rustia is an employee of Gilead Sciences. L.N. Walker is an employee of Harpoon Therapeutics.
: Advarra d/b/a Schulman Associates IRB, a central institutional review board, reviewed and approved all study materials prior to initiating recruitment and data collection.
: Informed consent was obtained from all participants prior to commencing enrollment.
: All authors provided this consent.
: Qualified researchers may request access to certain data and related study documents consistent with the Principles for Responsible Clinical Trial Data Sharing. Interested researchers can use ExternalRef removed to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care.
: Not applicable.
: All authors contributed to the study design, and analysis and interpretation of data. All authors contributed to critical revisions of the article and provided their final approval for publication.